{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:21:29Z","timestamp":1787678489920,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110237","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:03:59Z","timestamp":1783494239000},"page":"110237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enhanced oral absorption and anti-colorectal cancer efficacy of trifluridine by interfering with both TPase and UPase"],"prefix":"10.1016","volume":"180","author":[{"given":"Shulin","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyanto Teguh","family":"Widodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110237_bb0010","first-page":"357","article-title":"Fluoropyrimidine therapy in gastrointestinal cancer","volume":"7","author":"Sonbol","year":"2025","journal-title":"JACC: CardioOncology"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110237_bb0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","article-title":"TAS-102, a novel antitumor agent: a review of the mechanism of action","volume":"41","author":"Lenz","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110237_bb0020","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1535-7163.MCT-14-0236","article-title":"Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks","volume":"14","author":"Matsuoka","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41420-024-02083-3","article-title":"The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activity","volume":"10","author":"Wakasa","year":"2024","journal-title":"Cell Death Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110237_bb0030","first-page":"249","article-title":"An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA","volume":"13","author":"Emura","year":"2004","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110237_bb0035","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.trecan.2022.01.018","article-title":"Multifunctional role of thymidine phosphorylase in cancer","volume":"8","author":"Warfield","year":"2022","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41392-025-02272-1","article-title":"Purine nucleoside phosphorylase dominates influenza a virus replication and host hyperinflammation through purine salvage","volume":"10","author":"Yue","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110237_bb0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers10070240","article-title":"Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism","volume":"10","author":"Tsesmetzis","year":"2018","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110237_bb0050","first-page":"449","article-title":"Trifluridine\/tipiracil: old drug, new tricks","volume":"7","author":"Jeffers","year":"2016","journal-title":"J. Adv. Pract. Oncol."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110237_bb0055","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-016-0633-9","article-title":"Trifluridine\/Tipiracil: A review in metastatic colorectal cancer","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110237_bb0060","first-page":"418","article-title":"Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo","volume":"12","author":"Sun","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110237_bb0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.07.057","article-title":"Therapeutic-oligonucleotides activated by nucleases (TOUCAN): a nanocarrier system for the specific delivery of clinical nucleoside analogues","volume":"361","author":"Borsa","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2026.110237_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114245","article-title":"A general nanoplatform for nucleotide drug delivery: from molecular binding to antiviral therapy","volume":"387","author":"Zhou","year":"2025","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110237_bb0075","first-page":"65","article-title":"Current prodrug strategies for improving oral absorption of nucleoside analogues","volume":"9","author":"Zhang","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110237_bb0080","first-page":"631","article-title":"A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates","volume":"14","author":"Sun","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110237_bb0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jconrel.2023.07.035","article-title":"Chitooligosaccharide reconstitutes intestinal mucus layer to improve oral absorption of water-soluble drugs","volume":"360","author":"Qi","year":"2023","journal-title":"J. Control. Release"},{"issue":"20","key":"10.1016\/j.bioorg.2026.110237_bb0090","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110237_bb0095","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110237_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10637-016-0409-9","article-title":"A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone","volume":"35","author":"Cleary","year":"2017","journal-title":"Investig. New Drugs"},{"issue":"18","key":"10.1016\/j.bioorg.2026.110237_bb0105","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager Gerald","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/s12885-024-12447-8","article-title":"Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Aquino de Moraes","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110237_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.106059","article-title":"Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines","volume":"123","author":"Cheng","year":"2026","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110237_bb0120","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.apsb.2023.11.002","article-title":"Targeting FAP\u03b1-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis","volume":"14","author":"Fan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110237_bb0125","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.apsb.2025.03.016","article-title":"Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation","volume":"15","author":"Lin","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110237_bb0130","first-page":"669","article-title":"FDA approves ultra-orphan drug on a 4-patient trial","volume":"14","author":"Mullard","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110237_bb0135","doi-asserted-by":"crossref","first-page":"e21689","DOI":"10.1200\/JCO.2016.34.15_suppl.e21689","article-title":"Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities","volume":"34","author":"Ma","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110237_bb0140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110237_bb0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bcp.16319","article-title":"Review of the fluoropyrimidine antidote uridine triacetate","volume":"91","author":"Thompson","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110237_bb0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejps.2017.08.002","article-title":"Prodrugs-recent approvals and a glimpse of the pipeline","volume":"109","author":"Rautio","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110237_bb0155","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","article-title":"Personalized mapping of drug metabolism by the human gut microbiome","volume":"181","author":"Javdan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110237_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106922","article-title":"Characterising and preventing the gut microbiota's inactivation of trifluridine, a colorectal cancer drug","volume":"203","author":"McCoubrey","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110237_bb0165","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s12276-025-01402-7","article-title":"Uridine as a hub in cancer metabolism and RNA biology","volume":"57","author":"Choi","year":"2025","journal-title":"Exp. Mol. Med."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110237_bb0170","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1016\/j.apsb.2024.08.027","article-title":"Solubilization techniques used for poorly water-soluble drugs","volume":"14","author":"Xie","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0175","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2005.11.013","article-title":"Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs","volume":"111","author":"Jinno","year":"2006","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110237_bb0180","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/ph18081089","article-title":"Novel strategies for the formulation of poorly water-soluble drug substances by different physical modification strategies with a focus on peroral applications","volume":"18","author":"Quodbach","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.110237_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114513","article-title":"Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs","volume":"204","author":"Nyamba","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bioorg.2026.110237_bb0190","article-title":"Uridine metabolism and its role in glucose, lipid, and amino acid homeostasis","volume":"1","author":"Zhang","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bioorg.2026.110237_bb0195","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.2147\/JIR.S506308","article-title":"The role of uridine in health and disease","volume":"18","author":"Song","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bioorg.2026.110237_bb0200","doi-asserted-by":"crossref","first-page":"1360891","DOI":"10.3389\/fphys.2024.1360891","article-title":"Uridine and its role in metabolic diseases, tumors, and neurodegenerative diseases","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0205","first-page":"5","article-title":"Effect of uridine coadministration on 5\u2032-deoxy-5-fluorouridine disposition in rats","volume":"22","author":"Au","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110237_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127119","article-title":"Interfacial and self-association behaviour of poloxamer 188 in aqueous solutions","volume":"424","author":"Bollenbach","year":"2025","journal-title":"J. Mol. Liq."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110237_bb0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters-A review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.bioorg.2026.110237_bb0220","first-page":"262","article-title":"Pyrimidine nucleotide phosphorylase in rodents and human","volume":"8","author":"Shirasaka","year":"1981","journal-title":"Jpn. J. Cancer Chemother."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110237_bb0225","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2133\/dmpk.19.206","article-title":"Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor","volume":"19","author":"Tsuchiya","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110237_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031808","article-title":"5-fluorouracil induced intestinal mucositis via nuclear factor-\u03baB activation by transcriptomic analysis and in vivo bioluminescence imaging","volume":"7","author":"Chang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110237_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126121","article-title":"Aligning organ-specific toxicities with formulation strategies: a rational design approach to chemotherapy optimization","volume":"684","author":"Lu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2026.110237_bb0240","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.taap.2018.06.012","article-title":"Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency","volume":"353","author":"Garcia","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600773X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600773X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:45:03Z","timestamp":1787676303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600773X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"alternative-id":["S004520682600773X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110237","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced oral absorption and anti-colorectal cancer efficacy of trifluridine by interfering with both TPase and UPase","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110237"}}